Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic L... ( DETROIT Nov. 12 /- Caraco Pharmac...)

Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)

Date:11/12/2007

DETROIT, Nov. 12 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Lamotrigine Tablets (lamotrigine), 25 mg, 100 mg, 150 mg, and 200 mg. Final approval to market this product is anticipated subsequent to the expiry of patent protection on January 22, 2009.

Lamotrigine is indicated as adjunctive therapy for partial seizures (the generalized seizures of Lennox-Gastaut syndrome), is indicated for conversion to monotherapy in adults with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED, and is indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy.

This tentative approval is the bioequivalent to Lamictal(R), a registered trademark of GlaxoSmithKline. Lamictal(R) tablets had U.S. sales of approximately $1.89 billion for the 12-month period ended September 30, 2007, according to IMS Data.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are extremely pleased to receive this tentative approval and look forward to the expiration date of the patent in January 2009, which will allow Caraco to market the product. We feel that generic Lamictal(R) will be a positive addition to our portfolio by expanding our product offerings."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceu
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
11. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007

Post Your Comments:

(Date:12/1/2009).... 1 The Kerlan Jobe Ort...ngeles, has agreed to pay the United States $3 mil...l kickbacks from HealthSouth Corporation, the Just...tlement resolves allegations that HealthSouth paid...ion grants, donations to the Kerlan Jobe Foundatio...

(Date:12/1/2009)...ec. 1 A decision issued today by a... Board (NLRB) has put at risk the guaranteed raise...manente RNs, social workers, and professionals in ...rs to achieve standards at Kaiser that give us sec...e our patients need," said Jeanette Cryer, License...

(Date:12/1/2009)...gests that criteria based on computed tomography (...iver metastases after chemotherapy with the drug b...ll survival, according to a study in the December ...b to cytotoxic (toxic to cells) chemotherapy is as...tage IV colorectal cancer and higher pathologic re...

(Date:12/1/2009)...NS, Dec. 1 The American...High School Student Symposium at the New Orleans M... The symposium, which encourages an interest in he...earch, is held in conjunction with the Society,s 5...the opportunity to explore research on sickle cell...

(Date:12/1/2009)...Dec. 1 The government of Mexico Ci...ter for biomedical and nanomedical research, calle...search and development will be integrated with the... Spanish speaking university in the world. The re... 2010, has been designed by the internationally-ac...

Breaking Medicine News(10 mins):Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2 Health News:Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy 2 Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2 Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 2 Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 3 Health News:Mexico City to Build World-Class Hub for Medical Research 2

[0] Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations [0] Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy [0] Criteria based on CT imaging after chemotherapy may help predict survival [1] ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum [1] Mexico City to Build World-Class Hub for Medical Research

... EPS Growth of 53.3 Percent) - , , - Confirms Dou...reased 2009 Dividend by 11 Percent - , , ABBOTT... announced financial results for the first quarter... above the mid-point of Abbott,s previous first-qu...

...upply today announced that after only 20 months it...will now officially be known as Simplex Healthcare... April 15, 2009 -- Simplex Diabetic Supply today a...ur company has accomplished our initial mission of...

...BRA and Medicare considerations; people with disab...althcare coverage , Belle...rovisions in the 2009 American Recovery and Reinve...ing to Allsup , a leading provider of Social Secu...

...to represent executive board and individual union ...on on recognition of collective bargaining rights ...April 15, 2009 -- Taubman Kimelman & Soroka ,...by Local 2222 of the American Federation of Govern...

... issue of the Journal of Clinical Sleep Medicine ...ing sleep disorders in adults with a traumatic bra...ay result in the objective resolution of the sleep...sleep apnea (OSA), three months of treatment with ...

...arasites in east and west Africa carry different r...tiveness of sulfadoxine as an antimalarial drug ma...ations for the manner in which malaria control cam...ffective than working in isolation in each country...

Abbott Reports 16 Percent Earnings Growth in First Quarter; Confirms Double-Digit Earnings Growth Outlook for 2009 Simplex Diabetic Supply Changes Its Name to Simplex Healthcare Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act Taubman Kimelman & Soroka Retained by AFGE Local 2222 to Advise in Organizing of New York and New Jersey Transportation Security Officers Treating sleep disorders in people with traumatic brain injury may not eliminate symptoms Discovery of variations in resistance to sulfadoxine across Africa

(Date:12/1/2009)...Dec. 1 Reportlinker.com announces ...its catalogue: ,, Direct to Consumer (DTC) Adv...arket Outlook, Regulatory Landscape and Case Studi...rect-to-Consumer-DTC-Advertising-in-Pharmaceutical...andscape-and-Case-Studies.html ,, Summary ,...

(Date:12/1/2009)..., Dec. 1 CeloNova BioSciences, Inc...medical devices and of specialty implants, today a...r, Thomas A. Gordy, will give an opening address f...diovascular Interventions Conference in Tel Aviv, ...rest behind and focus the rich intellectual resour...

(Date:12/1/2009)... Tenn., Dec. 1 Cumberlan...today that an independently conducted study of Ace...s N-acetylcysteine, as a cost-saving treatment for...2, Number 4 of the peer-reviewed Journal of Medic...y concludes that Acetadote is a less costly treatm...

Breaking Medicine Technology:Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7 Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8 CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices 2 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 2 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 3 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 4 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 5 Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 6 Super sleepers could help super sizers 21 9034 1 Super sleepers could help super sizers 21 9034 2 Reading the brain without poking it 9033 1 Reading the brain without poking it 9033 2 Reading the brain without poking it 9033 3 Reading the brain without poking it 9033 4 Reading the brain without poking it 9033 5 GP bodies support guidelines for use of patient records in medical research 50226 1 GP bodies support guidelines for use of patient records in medical research 50226 2

[0] Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies [0] CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices [0] Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems

...v. 7 Data from an investigational,open-label, ran...f,PROCRIT(R) (Epoetin alfa) in treating anemia in ...(CKD) were presented today at the American Society...sing groups, including the FDA-approved,three-time...d,once-every-two-weeks (Q2W) investigational regim...

...ov. 7 Spherix Incorporated,(Nasdaq: SPEX ) repor...cal,trial of its potential type 2 diabetes drug, N...India are to provide more than 300 patients spread...ow that enrollment efforts,are underway in India, ...d,on schedule as reported during the May 2008 Annu...

Other Medicine Technology:Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6 Patient Recruitment Begins in India for Phase 3 Diabetes Trial 2

Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting Patient Recruitment Begins in India for Phase 3 Diabetes Trial

Innova 3100 Water Bath Shaker

55D Double Platform Shaker 11 x 14

Innova 5000 Muti-Tier Shaker

...up to 16 of AutoGen's tube units to prepare 96 sam...te for bacterial cultures and enzyme reactions, su... simplify your DNA extraction process by preparing...lacing our 6-hole tube units directly onto one of ...

Medicine Products:

Innova 3100 Water Bath Shaker 55D Double Platform Shaker 11 x 14 Innova 5000 Muti-Tier Shaker AutoIncubator 96

Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic L...( DETROIT Nov. 12 /- Caraco Pharmac...),Health